B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The trial is set to take place at sites across several European countries including Spain, the UK and Belgium.

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways ...

SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies ... targeting CD19/CD20, has administered ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...

“Biologically, mantle cell is a CD20 bright lymphoma, leading us to hypothesize that targeting both CD19, which we know is an effective target in CAR-T, and CD20, which is effectively harnessed ...

Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. vi Epcoritamab (approved under the brand name EPKINLY ® in ...